Quote
Challenging recent claims linking antidepressant use to suicidal behavior, a new UCLA study shows that American suicide rates have dropped steadily since the introduction of Prozac and other serotonin reuptake inhibitor (SSRI) drugs. Published in the February edition of the journal Nature Reviews Drug Discovery, the authors caution that regulatory actions to limit SSRI prescriptions may actually increase death rates from untreated depression, the No. 1 cause of suicide.
New Report Concludes SSRI Antidepressants Do Not Increase Suicidal behavior in Youth with Depression
Quote
WASHINGTON -- Selective Serotonin Reuptake Inhibitors (SSRI) antidepressants do not increase the risk of suicidal thinking or suicide attempts in youth, according to a new
report released in late January by the American College of Neuropsychopharmacology
(ACNP). The report also noted that several SSRIs have been shown to be
effective for treating depression in this population. ACNP appointed a
special task force of the nation's leading scientists in the field to review
the available research on the use of antidepressants and youth under 18 years
of age.
report released in late January by the American College of Neuropsychopharmacology
(ACNP). The report also noted that several SSRIs have been shown to be
effective for treating depression in this population. ACNP appointed a
special task force of the nation's leading scientists in the field to review
the available research on the use of antidepressants and youth under 18 years
of age.
Full Text
Suicide Rates Have Decreased With Increased Use of SSRIs, New-Generation Non-SSRIs
Quote
Suicide Rates Have Decreased With Increased Use of SSRIs, New-Generation Non-SSRIs
Laurie Barclay, MD
Feb. 7, 2005 — Suicide rates have dropped in association with increased use of selective serotonin reuptake inhibitors (SSRI) and new-generation non-SSRIs, according to the results of an analysis of a U.S. Centers for Disease Control and Prevention (CDC) national vital statistics study published in the February issue of the Archives of General Psychiatry. However, the investigators acknowledge that this type of data cannot demonstrate causal relationships.
"Approximately 30,000 people die annually by suicide in the US," write Robert D. Gibbons, PhD, from the University of Illinois at Chicago, and colleagues. "Although 60% of suicides occur during a mood disorder, mostly untreated, little is known about the relationship between antidepressant medication use and the rate of suicide in the US."
Using data from all US individuals who committed suicide between 1996 and 1998, the investigators extracted national county-level suicide rate data broken down by age, sex, income, and race. They also determined national county-level antidepressant prescription data, expressed as the number of pills prescribed. The main outcome was the suicide rate in each county expressed as the number of suicides for a given population size.
After adjustment for age, sex, race, income, and county-to-county variability in suicide rates, antidepressant medication prescription was not significantly related to suicide rate. However, within individual classes of antidepressants, prescriptions for SSRIs and other new-generation non-SSRI antidepressants, such as nefazodone hydrochloride, mirtazapine, bupropion hydrochloride, and venlafaxine hydrochloride, were associated with lower suicide rates, both within and among counties. There was a positive association between tricyclic antidepressant (TCA) prescription and suicide rate. In rural areas, higher suicide rates were associated with fewer antidepressant prescriptions, lower income, and relatively more prescriptions for TCAs.
"The aggregate nature of these observational data preclude a direct causal interpretation of the results," the authors write. "A high number of TCA prescriptions may be a marker for those counties with more limited access to quality mental health care and inadequate treatment and detection of depression, which in turn lead to increased suicide rates. By contrast, increases in prescriptions for SSRIs and other new-generation non-SSRIs are associated with lower suicide rates both between and within counties over time and may reflect antidepressant efficacy, compliance, a better quality of mental health care, and low toxicity in the event of a suicide attempt by overdose."
Laurie Barclay, MD
Feb. 7, 2005 — Suicide rates have dropped in association with increased use of selective serotonin reuptake inhibitors (SSRI) and new-generation non-SSRIs, according to the results of an analysis of a U.S. Centers for Disease Control and Prevention (CDC) national vital statistics study published in the February issue of the Archives of General Psychiatry. However, the investigators acknowledge that this type of data cannot demonstrate causal relationships.
"Approximately 30,000 people die annually by suicide in the US," write Robert D. Gibbons, PhD, from the University of Illinois at Chicago, and colleagues. "Although 60% of suicides occur during a mood disorder, mostly untreated, little is known about the relationship between antidepressant medication use and the rate of suicide in the US."
Using data from all US individuals who committed suicide between 1996 and 1998, the investigators extracted national county-level suicide rate data broken down by age, sex, income, and race. They also determined national county-level antidepressant prescription data, expressed as the number of pills prescribed. The main outcome was the suicide rate in each county expressed as the number of suicides for a given population size.
After adjustment for age, sex, race, income, and county-to-county variability in suicide rates, antidepressant medication prescription was not significantly related to suicide rate. However, within individual classes of antidepressants, prescriptions for SSRIs and other new-generation non-SSRI antidepressants, such as nefazodone hydrochloride, mirtazapine, bupropion hydrochloride, and venlafaxine hydrochloride, were associated with lower suicide rates, both within and among counties. There was a positive association between tricyclic antidepressant (TCA) prescription and suicide rate. In rural areas, higher suicide rates were associated with fewer antidepressant prescriptions, lower income, and relatively more prescriptions for TCAs.
"The aggregate nature of these observational data preclude a direct causal interpretation of the results," the authors write. "A high number of TCA prescriptions may be a marker for those counties with more limited access to quality mental health care and inadequate treatment and detection of depression, which in turn lead to increased suicide rates. By contrast, increases in prescriptions for SSRIs and other new-generation non-SSRIs are associated with lower suicide rates both between and within counties over time and may reflect antidepressant efficacy, compliance, a better quality of mental health care, and low toxicity in the event of a suicide attempt by overdose."
From: http://www.medscape....e/498841?src=mp
This post has been edited by Velvet Elvis: 25 May 2005 - 03:07 PM

Sign In
Register
Help
Start a new topic
Add Reply


MultiQuote